Testing where to aim extra rectal radiation before surgery
Part of Cancer, Digestive system clinical trials.
This trial tests the best place to target an “extra boost” of radiation inside the rectum for certain rectal cancer patients. It may help guide more precise treatment planning before they have total mesorectal excision (TME) surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to sign consent
- You have rectal cancer confirmed by pathology after prior chemoradiation or radiation
- Your cancer is expected to be treated with TME surgery after this study
- There must be at least 6 weeks between your last radiation/chemoradiation and your surgery
- You did not receive brachytherapy (radiation given directly in/near the tumor) as part of your earlier treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a higher dose of radiation to rectal cancer tumors can help patients avoid surgery altogether. The goal is to shrink the tumor enough that surgery is no longer needed, preserving normal bowel function.
This study tests a new combination of treatment before surgery for high-risk rectal cancer. It combines a shorter course of radiation with chemotherapy and immunotherapy (which helps your immune system fight cancer) to see if it shrinks the tumor and improves outcomes.
This study looks at molecular (tumor biology) features of rectal cancer in people receiving standard short-course radiation. Your tissue and/or samples may be used to better understand the cancer and how it responds to treatment.
This trial compares two different surgery approaches for early-stage rectal cancer (T2N0M0) that is close to the anus. It tests whether a less invasive local removal followed by radiation works as well as more extensive surgery (total mesorectal excision).
This study looks at whether giving radiation or chemoradiation after removing an early-stage rectal cancer can improve outcomes for patients who choose not to have standard surgery to remove the whole rectum. It aims to see how well this approach works in real-world practice.
This Phase 2 study tests a “total neoadjuvant” approach, meaning you receive cancer treatment before surgery, to improve safety and effectiveness for rectal cancer. It may help by shrinking the tumor and planning a more effective operation, while researchers carefully track side effects.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.